MX9202619A - Derivados de oxa tiolano cristalino, metodo para su preparacion y formulacion farmaceutica que los contiene. - Google Patents

Derivados de oxa tiolano cristalino, metodo para su preparacion y formulacion farmaceutica que los contiene.

Info

Publication number
MX9202619A
MX9202619A MX9202619A MX9202619A MX9202619A MX 9202619 A MX9202619 A MX 9202619A MX 9202619 A MX9202619 A MX 9202619A MX 9202619 A MX9202619 A MX 9202619A MX 9202619 A MX9202619 A MX 9202619A
Authority
MX
Mexico
Prior art keywords
tiolano
cristalino
oxa
derivatives
preparation
Prior art date
Application number
MX9202619A
Other languages
English (en)
Inventor
Paul Ravenscroft
Tony Gordon Roberts
Paul Evans
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10696001&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX9202619(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MX9202619A publication Critical patent/MX9202619A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Secondary Cells (AREA)
  • Medicinal Preparation (AREA)
MX9202619A 1991-06-03 1992-06-02 Derivados de oxa tiolano cristalino, metodo para su preparacion y formulacion farmaceutica que los contiene. MX9202619A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB919111902A GB9111902D0 (en) 1991-06-03 1991-06-03 Chemical compounds

Publications (1)

Publication Number Publication Date
MX9202619A true MX9202619A (es) 1992-12-01

Family

ID=10696001

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9202619A MX9202619A (es) 1991-06-03 1992-06-02 Derivados de oxa tiolano cristalino, metodo para su preparacion y formulacion farmaceutica que los contiene.

Country Status (31)

Country Link
US (1) US5905082A (es)
EP (2) EP0517145B1 (es)
JP (1) JP2851480B2 (es)
KR (1) KR100244008B1 (es)
AP (1) AP300A (es)
AT (1) ATE212630T1 (es)
AU (2) AU656379B2 (es)
BG (1) BG60914B1 (es)
CA (2) CA2311988C (es)
CZ (1) CZ284513B6 (es)
DE (1) DE69232387T2 (es)
DK (1) DK0517145T3 (es)
ES (1) ES2171158T3 (es)
GB (1) GB9111902D0 (es)
GE (1) GEP19991834B (es)
HK (1) HK1009599A1 (es)
IE (2) IE921780A1 (es)
IL (1) IL102073A (es)
IS (2) IS1867B (es)
MX (1) MX9202619A (es)
NO (1) NO301713B1 (es)
NZ (1) NZ242981A (es)
OA (1) OA09913A (es)
PT (1) PT517145E (es)
RU (1) RU2102393C1 (es)
SG (1) SG52455A1 (es)
SK (1) SK281249B6 (es)
TW (1) TW254939B (es)
UA (1) UA41265C2 (es)
WO (1) WO1992021676A1 (es)
ZA (1) ZA924007B (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4581979A (en) * 1983-07-01 1986-04-15 Automotive Products Plc Shipping and installation restraining clip for master cylinder input member
US6642245B1 (en) 1990-02-01 2003-11-04 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US6069252A (en) * 1990-02-01 2000-05-30 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nucleoside enantiomers
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US6812233B1 (en) 1991-03-06 2004-11-02 Emory University Therapeutic nucleosides
US5817667A (en) * 1991-04-17 1998-10-06 University Of Georgia Research Foudation Compounds and methods for the treatment of cancer
GB9116601D0 (en) * 1991-08-01 1991-09-18 Iaf Biochem Int 1,3-oxathiolane nucleoside analogues
US6177435B1 (en) 1992-05-13 2001-01-23 Glaxo Wellcome Inc. Therapeutic combinations
US20020120130A1 (en) 1993-09-10 2002-08-29 Gilles Gosselin 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
IL115156A (en) 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
US6391859B1 (en) 1995-01-27 2002-05-21 Emory University [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
US5703058A (en) * 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US5808040A (en) * 1995-01-30 1998-09-15 Yale University L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
ES2276404T3 (es) 1995-06-07 2007-06-16 Emory University Nucleosidos con actividad antivirus de la hepatitis-b.
US5914332A (en) * 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
EP0938321B1 (en) 1996-06-25 2004-01-14 Glaxo Group Limited Combinations comprising vx478, zidovudine and 3tc for use in the treatment of hiv
US5753789A (en) * 1996-07-26 1998-05-19 Yale University Oligonucleotides containing L-nucleosides
TW536403B (en) * 1997-03-24 2003-06-11 Glaxo Group Ltd An ethanol and ethylenediaminetetraacetic acid free pharmaceutical composition comprising lamivudine and exhibiting antimicrobial preservative efficacy
US6436948B1 (en) 2000-03-03 2002-08-20 University Of Georgia Research Foundation Inc. Method for the treatment of psoriasis and genital warts
WO2003079972A2 (en) 2002-02-22 2003-10-02 New River Parmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
KR101015510B1 (ko) * 2001-03-01 2011-02-16 길리애드 사이언시즈, 인코포레이티드 시스-ｆｔｃ의 다형 및 기타 결정형
CA2351049C (en) 2001-06-18 2007-03-13 Brantford Chemicals Inc. Process for recovery of the desired cis-1,3-oxathiolane nucleosides from their undesired trans-isomers
WO2003027106A1 (en) * 2001-09-25 2003-04-03 Cadila Healthcar Limited Process for the preparation of crystalline polymorph ii of lamivudine
US20050287177A1 (en) * 2002-11-08 2005-12-29 Glaxo Group Unlimited And Smithkline Beecham Corp. Pharmaceutical compositions
AU2004206821C1 (en) 2003-01-14 2009-10-01 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
DE602005011321D1 (de) * 2004-11-10 2009-01-08 Novartis Vaccines & Diagnostic Deamidiertes interferon-beta
US20060242012A1 (en) * 2005-04-22 2006-10-26 Sumit Agarwal Determining or scoring properties to solicit to join ad network using advertiser or aggregated advertiser interest
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
ES2357159T3 (es) * 2006-04-18 2011-04-19 Lupin Ltd. Forma cristalina novedosa de lamivudina.
WO2009031026A2 (en) * 2007-09-06 2009-03-12 Combino Pharm, S.L. Novel pharmaceutical compositions
WO2009037538A2 (en) * 2007-09-17 2009-03-26 Aurobindo Pharma Ltd Process for the preparation of lamivudine form i
CN101918393A (zh) * 2007-11-29 2010-12-15 兰贝克赛实验室有限公司 拉米夫定的晶形i及其制备方法
SI2225232T1 (sl) * 2007-11-29 2012-12-31 Ranbaxy Laboratories Limited Postopek za pripravo substituiranih 1,3-oksatiolanov
BRPI0820224A2 (pt) * 2007-11-29 2015-06-16 Ranbaxy Lab Ltd Composto de fórmula iii ou seus estereoisômeros; processo para sua preparação e seu uso; uso de um composto de formula iii(a) ou iii(b) em um processo para a preparação de lamivudina de fórmula i(a) ou um composto de fórmula i(c); processo para preparação de lamivudina de fórmula i(a)
WO2009127996A1 (en) * 2008-04-17 2009-10-22 Ranbaxy Laboratories Limited Novel crystalline form of lamivudine
US8536151B2 (en) 2008-09-01 2013-09-17 Hetero Research Foundation Process for preparing lamivudine polymorph form
WO2010055526A1 (en) * 2008-11-12 2010-05-20 Lupin Limited A novel polymorph of emtricitabine and a process for preparing of the same
CN101993439B (zh) * 2009-03-24 2013-04-24 福建广生堂药业股份有限公司 拉米夫定晶型及其制备方法
CN101531656B (zh) * 2009-03-24 2010-12-08 福建广生堂药业有限公司 拉米夫定晶型及其制备方法
EP2435052B1 (en) * 2009-05-27 2015-07-15 Hetero Research Foundation Solid oral dosage forms of lamivudine with isomalt
EP2454244B1 (en) 2009-07-15 2013-06-26 Lupin Limited An improved process for preparation of efavirenz
ES2540074T3 (es) 2009-10-14 2015-07-08 Mylan Laboratories Limited Proceso para la preparación de lamivudina y nuevas sales en la fabricación de la misma
TR201807704T4 (tr) 2010-01-27 2018-06-21 Viiv Healthcare Co Anti-viral tedavi.
WO2011095987A1 (en) * 2010-02-03 2011-08-11 Matrix Laboratories Ltd. Novel process for the preparation of cis-nucleoside derivative
JP2013519676A (ja) * 2010-02-12 2013-05-30 メルク・シャープ・エンド・ドーム・コーポレイション ラミブジン形態ｉの調製
EP2579892A2 (en) 2010-06-09 2013-04-17 Vaccine Technologies, Incorporated Therapeutic immunization in hiv infected subjects receiving stable antiretroviral treatment
WO2013021290A1 (en) 2011-08-05 2013-02-14 Lupin Limited A stereoselective process for preparation of 1,3-oxathiolane nucleosides
WO2013168066A1 (en) 2012-05-05 2013-11-14 Lupin Limited An improved process for the manufacture of lamivudine form i.
CN114099454B (zh) * 2020-08-31 2023-06-27 长春海悦药业股份有限公司 一种拉米夫定片及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
GB9009861D0 (en) * 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
US5179104A (en) * 1990-12-05 1993-01-12 University Of Georgia Research Foundation, Inc. Process for the preparation of enantiomerically pure β-D-(-)-dioxolane-nucleosides
US5248776A (en) * 1990-12-05 1993-09-28 University Of Georgia Research Foundation, Inc. Process for enantiomerically pure β-L-1,3-oxathiolane nucleosides

Also Published As

Publication number Publication date
KR930000511A (ko) 1993-01-15
EP0517145A1 (en) 1992-12-09
IL102073A (en) 1996-05-14
IS4268A (is) 1995-02-27
CA2311988A1 (en) 1992-12-04
IE921780A1 (en) 1992-12-16
BG60914B1 (bg) 1996-06-28
CZ261293A3 (en) 1994-04-13
JP2851480B2 (ja) 1999-01-27
NO301713B1 (no) 1997-12-01
IL102073A0 (en) 1993-01-14
SK125793A3 (en) 1994-11-09
NO922182D0 (no) 1992-06-02
EP0517145B1 (en) 2002-01-30
CA2070230C (en) 2004-08-03
CA2311988C (en) 2005-11-15
JPH06211848A (ja) 1994-08-02
RU2102393C1 (ru) 1998-01-20
AU1736192A (en) 1993-03-11
UA41265C2 (uk) 2001-09-17
US5905082A (en) 1999-05-18
GEP19991834B (en) 1999-11-05
DE69232387D1 (de) 2002-03-14
KR100244008B1 (ko) 2000-03-02
NO922182L (no) 1992-12-04
EP1099700A1 (en) 2001-05-16
PT517145E (pt) 2002-07-31
OA09913A (en) 1994-09-15
GB9111902D0 (en) 1991-07-24
CA2070230A1 (en) 1992-12-04
IS1867B (is) 2003-05-02
ZA924007B (en) 1993-04-28
TW254939B (es) 1995-08-21
AU1881092A (en) 1993-01-08
NZ242981A (en) 1994-04-27
ES2171158T3 (es) 2002-09-01
AP9200395A0 (en) 1992-07-31
ATE212630T1 (de) 2002-02-15
SG52455A1 (en) 1998-09-28
DK0517145T3 (da) 2002-05-06
DE69232387T2 (de) 2002-09-26
HK1009599A1 (en) 1999-06-04
AU656379B2 (en) 1995-02-02
IE20020782A1 (en) 2003-04-02
IS3873A (is) 1992-12-04
AP300A (en) 1994-01-20
WO1992021676A1 (en) 1992-12-10
SK281249B6 (sk) 2001-01-18
CZ284513B6 (cs) 1998-12-16
BG98254A (bg) 1994-07-29

Similar Documents

Publication Publication Date Title
MX9202619A (es) Derivados de oxa tiolano cristalino, metodo para su preparacion y formulacion farmaceutica que los contiene.
MX9202289A (es) Nuevos derivados de tiopiranopirrol, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
MX9204140A (es) Nuevos derivados de analogos de taxol, procedimiento para su preparacion y composicion farmaceutica que los contienen.
MX9205280A (es) Derivados de benzanilida, procedimiento para su preparacion y composicion farmaceutica que los contiene.
MX9200180A (es) DERIVADOS DE LA 5H-PIRROL (3,4-b) PIRAZINA OPTICAMENTE ACTIVOS, PROCEDIMIENTO PARA SU PREPARACION Y COMPOSICION FARMACEUTICA QUE LOS CONTIENE.
MX9206503A (es) Nuevos derivados de lupano, proceso para su preparacion y composicion farmaceutica que los contiene.
MX9206541A (es) Derivados de acido acetico, procedimiento para su preparacion y composicion farmaceutica que los contiene.
MX9205908A (es) Derivados heterobiarilicos, medicamentos que contienen estos compuestos y procedimientos para su preparacion
MX9102501A (es) Derivados de metano sulfonamida, composiciones farderivados de metanosulfonamida, composiciones farmaceuticas que los contienen y procedimiento para smaceuticas que los contienen y procedimiento para u preparacion. su preparacion.
MX9203228A (es) Derivados de los acidos 7-aza iso indolinil-quinolon y naftiridon carboxilicos, procedimiento para su obtencion y medicamentos que los contienen.
MX9205768A (es) Derivados de 3-fenilpirazoles, procedimiento para su preparacion y composicion fungicida que los contiene
MX9200374A (es) Nuevos esteres esteroides, procedimiento para su preparacion y preparacion farmaceutica que los contiene.
MX9204844A (es) Derivados de benzodioxano, procedimiento para su preparacion composiciones farmaceuticas que los contienen.
MX9100317A (es) Nuevos compuestos de beta-lactama,procedimiento para su preparacion y composiciones farmaceuticas que los contienen
MX9201295A (es) Derivados de benzofurano, proceso para su preparacion y composicion farmaceutica que los contienen.
MX9202982A (es) Derivados de los acidos quinolon - y naftiridon - carboxilicos, procedimiento para su obtencion y medicamentos que los contienen.
MX9207383A (es) Derivados de 2-imidazolin-5-onas y 2-imidazolin-5-tionas, procedimiento para su preparacion y composiciones fungicidas que los contienen.
MX9204563A (es) Nuevos derivados de la (2-alquil-3-piridil)-metilpiperazina y composicion farmaceutica que los comprende.
MX9205916A (es) Derivados de acido ciclohexanoacetico, proceso para su preparacion y composicion farmaceutica que los comprende
MX9201058A (es) Derivados ciclicos de cetal, procedimiento para supreparacion y composicion farmaceutica que los contiene.
MX9205155A (es) Derivados heterociclicos n-substituidos, procedimiento para su preparacion y composicion farmaceutica que los contiene.
MX9201847A (es) Derivados heterociclicos de antiserotoninas, procedimiento para su preparacion y medicamentos que los contienen.
MX9202300A (es) Derivados de benzofurano, procedimiento para su preparacion y composicion farmaceutica que los contiene.
MX9204395A (es) Derivados de 3-desoxi-manosamina, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
MX9205132A (es) Derivados de acidos carboxilicos heterociclicos, procedimiento para su obtencion y medicamentos que los contienen.

Legal Events

Date Code Title Description
FG Grant or registration
PD Change of proprietorship

Owner name: VIIV HEALTHCARE UK LIMITED